Sanchorawala, V. (May 26, 2017). A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, 130, . doi:10.1182/blood-2017-03-771220

"A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis / Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan O. Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai-Min Hui, Raymond L. Comenzo and Giampaolo Merlini" Blood .

Sanchorawala, Vaishali. "A Phase 1/2 Study of the Oral Proteasome Inhibitor Ixazomib in Relapsed or Refractory AL Amyloidosis." Blood 130 (May 26, 2017).